Glargine Promotes Proliferation of Breast Adenocarcinoma Cell Line MCF-7 via AKT Activation

Abstract

Glargine is widely used as a long-acting insulin analogue in the treatment of diabetes mellitus. However, this insulin analogue has been recently suspected to be associated with an increased risk of cancer. The aim of this study was to investigate the influence of glargine on proliferation of breast adenocarcinoma cell line (MCF-7) and its possible mechanism. Effects of glargine and regular human insulin on the cell proliferation were tested in ER-positive MCF-7 cells by MTT assay. Apoptosis in MCF-7 cells was measured by flow cytometry. The protein levels of p-AKT, Bcl-2, and Bax were also determined by Western blotting and immunohistochemistry, respectively. The result showed that glargine (100, 200 nmol/l) stimulated proliferation of ER-positive MCF-7 cells compared with regular human insulin. At the same time, glargine decreased the percentage of early apoptosis in MCF-7 cells. Otherwise, glargine (100 nmol/l) stimulated the p-AKT in a time-dependent manner in MCF-7 cells. Furthermore, we found that glargine downregulated the level of Bax protein and upregulated that of Bcl-2 (p <0.05). These data show that glargine promote the proliferation of breast adenocarcinoma cells in vitro, probably by preventing apoptosis.

Key words

glargine - apoptosis - cancer - AKT

• References

• 1 Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174-183
• 2 Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: Insulin analogs. Endocr Rev 2001; 22: 706-717
• 3 Dawson LK, Hamilton LA. Risk of cancer in patients receiving insulin glargine. Am J Health Syst Pharm 2010; 67: 2025-2031
• 4 Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009; 52: 1732-1744
• 5 Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies – a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745-1754
• 6 Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, Marchionni N, Rotella CM. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010; 33: 1997-2003
• 7 Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52: 2499-2506
• 8 Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008; 114: 38-44
• 9 Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009; 25: 41-49
• 10 Erbel S, Reers C, Eckstein VW, Kleeff J, Buchler MW, Nawroth PP, Ritzel RA. Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 2008; 31: 1105-1111
• 11 Zelobowska K, Gumprecht J, Grzeszczak W. Mitogenic potency of insulin glargine. Endokrynol Pol 2009; 60: 34-39
• 12 Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005
• 13 Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-i receptor. Diabetologia 2010; 53: 2667-2675
• 14 Santos ED, Dieudonné MN, Leneveu MC, Sérazin V, Rincheval V, Mignotte B, Chouillard E, Mazancourt PD, Giudicelli Y, Pecquery R. Effects of 17β-Estradiol on Preadipocyte Proliferation in Human Adipose Tissue: Involvement of IGF1-R Signaling. Horm Metab Res 2010; 42: 514-520
• 15 Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: Insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96
• 16 Wilsbacher JL, Zhang Q, Tucker LA, Hubbard RD, Sheppard GS, Bamaung NY, Fidanze SD, Wang GT, Hu X, Davidsen SK, Bell RL, Wang J. Insulin-like growth factor-1 receptor and erbb kinase inhibitor combinations block proliferation and induce apoptosis through cyclin d1 reduction and bax activation. J Biol Chem 2008; 283: 23721-23730
• 17 Li P, Koike T, Qin B, Kubota M, Kawata Y, Jia YJ, Oshida Y. A High-fructose Diet Impairs Akt and PKCzeta Phosphorylation and GLUT4 Translocation in Rat Skeletal Muscle. Horm Metab Res 2008; 40: 528-532
• 18 Skurk T, Huber CA, Hauner H. Effect of Conditioned Media from Mature Human Adipocytes on Insulin-stimulated Akt/PKB Phosphorylation in Human Skeletal Muscle Cells: Role of BMI and Fat Cell Size. Horm Metab Res 2009; 41: 190-196
• 19 Liu S, Li Y, Lin T, Fan X, Liang Y, Heemann U. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Res Clin Pract 2011; 91: 177-182
• 20 Ciaraldi TP, Sasaoka T. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: Potential implications for metabolic and mitogenic activities. Horm Metab Res 2010; 43: 1-10
• 21 Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of mcl-1. Mol Cell 2006; 21: 749-760
• 22 Adams JM, Cory S. Life-or-death decisions by the bcl-2 protein family. Trends Biochem Sci 2001; 26: 61-66
• 23 Cory S, Adams JM. The bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656
• 24 Chen J, Chen X, Qin J. Effects of polysaccharides of the Euphoria Longan (Lour.) Steud on focal cerebral ischemia/reperfusion injury and its underlying mechanism. Brain Inj 2011; 25: 292-299
• 25 Mandelin 2nd AM, Pope RM. Myeloid cell leukemia-1 as a therapeutic target. Expert Opin Ther Targets 2007; 11: 363-373